Skip to main content

Advertisement

SpringerLink
Log in

Abnormal gene expression leads to poor prognosis in breast cancer patients in Bihar

  • Original Article
  • Published:
Comparative Clinical Pathology Aims and scope Submit manuscript

Abstract

With its highest mortality rate, the breast cancer outruns other gynecological cancers. For a long time, the breast cancer was associated with poor prognosis. But with the advent of analysis of expression level of different protein receptors (ER/PR and Her-2/neu) with the help of immunohistochemistry (IHC) has ushered us to a new era of treatment of cancer called immunotherapy.

Tissues sampled from 167 breast cancer patients at pathology labs of Mahavir Cancer Institute & Research Center, S S Hospital and Research Institute and NMCH, Patna, Bihar, India, were processed by a routine protocol.

Highest percentage of patients showed ER+/PR+ and least percentage of patients were characterized by ER+/PR− (p value <0.0001, hazard ratio, 95 % CI 2.537–21.603). A large number of patients (52.09 %) were classified under luminal C. Interestingly, 25.74 and 44.31 % of total patients aged within 30–50 tend to show ER−/PR− and Her-2/neu with p value <0.0081 (hazard ratio, 95 % CI 1.674–6.833) and 0.0313 (hazard ratio, 95 % CI 0.263–1.623), respectively.

The present endeavor was to classify the patients for their prognosis on the basis of hormonal and C-erb B2. The failure of the drug in ER−/PR− patients like tamoxifen is not a good sign to the oncologists. Herceptin on the other hand can play a good role in the treatment of greater percentage of patients showing Her-2/neu+. However, implementation of either new prognostic marker or more effective immunotherapy or both are warranted for effective treatment of breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168

    CAS  PubMed  Google Scholar 

  • Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S et al (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16:1340–1349

    CAS  PubMed  Google Scholar 

  • Baselga J, Seidman AD, Rosen PP et al (1997) Her-2 overexpression and paclitaxel sensitivity in breast cancer. Therapeutic implication. Oncology (Huntingt) 11(suppl 2):43–48

    CAS  Google Scholar 

  • Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G et al (2000) HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 18:3471–3479

    CAS  PubMed  Google Scholar 

  • Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S et al (1994) ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81:137–144

    Article  CAS  PubMed  Google Scholar 

  • Carlomagno C, Perrone F, Gallo C et al (1996) c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702–2708

    CAS  PubMed  Google Scholar 

  • Coon JS, Marcus E, Gupta-Burt S et al (2002) Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8:1061–1067

    CAS  PubMed  Google Scholar 

  • Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15):4429–4434

    Article  PubMed  Google Scholar 

  • Di Leo A, Gancberg D, Larsimont D et al (2002) Her-2 amplification and topoisomerase II α gene aberrations as predictive marker in node- positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-florouracil. Clin Cancer Res 8:1107–1116

    PubMed  Google Scholar 

  • Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM et al (1998) HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 4:7–12

    CAS  PubMed  Google Scholar 

  • Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J et al (2000) Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89:111–117

    Article  CAS  PubMed  Google Scholar 

  • Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J eds (2013) Cancer incidence in five continents. Globocan, IARC. http://ci5.iarc.fr last accessed on [01-11-2013]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

  • Foulkes WD, Steffansson IM, Chappuis PO et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482–1485

    Article  CAS  PubMed  Google Scholar 

  • Helsinki (2008) WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects, 59th WMA General Assembly, Seoul

    Google Scholar 

  • Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW (1999) Overexpression of c-erb B2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79:1220–1226

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huston JS, George AJ (2001) Engineered antibodies take center stage. Hum Antibodies 10:127–142

    CAS  PubMed  Google Scholar 

  • Kim R, Tanabe K, Uchida Y et al (2002) The role of Her-2 onco-protein in drug sensitivity in breast cancer (Review). Oncol Rep 9:3–9

    CAS  PubMed  Google Scholar 

  • Lakhani SR, Van DeVijver MJ, Jacquemier J et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with BRCA1and BRCA2. JClin Oncol 20:2310–2318

    Article  CAS  Google Scholar 

  • Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L et al (2002) Elevated serum HER-2/neu levels predict decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20:1467–1472

    Article  CAS  PubMed  Google Scholar 

  • Masood S, Bui MM (2002) Prognostic and predictive value of Her-2/neu oncogene in breast cancer. Microsc Res Tech 59:102–108

    Article  CAS  PubMed  Google Scholar 

  • McGuire WL, Chamness GC, Fuqua SA (1991) Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5:1571–1577

    Article  CAS  PubMed  Google Scholar 

  • Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh LD et al (2004) Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Modern Pathol 17:1545–1554

    Article  CAS  Google Scholar 

  • Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752

    Article  CAS  PubMed  Google Scholar 

  • Dhillon PK (2003) Breast cancer factsheet. South Asia Network for Chronic Disease, Public Health Foundation of India., pp 1–22

    Google Scholar 

  • Rilke F, Colnaghi MI, Cascinelli N et al (1991) Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49:44–49

    Article  CAS  PubMed  Google Scholar 

  • Ross JS, Fletcher JA, Linnette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307–325

    Article  CAS  PubMed  Google Scholar 

  • Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J (1998) Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462–469

    CAS  PubMed  Google Scholar 

  • Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418–8423

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tagliabue E, Menard S, Robertson JF, Harris L (1999) c-erbB-2 expression in primary breast cancer. Int J Biol Markers 14:16–26

    CAS  PubMed  Google Scholar 

  • Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first line of treatment of Her-2 overexpressing metastatic breast cancer. J Clin Oncol 20:719–726

    Article  CAS  PubMed  Google Scholar 

  • Yamauchi H, O’Neill A, Gelman R et al (1997) Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of Her-2/c-neu protein. J Clin Oncol 15:2518–2525

    CAS  PubMed  Google Scholar 

  • Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W et al (2014) MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One 9(5), e96228. doi:10.1371/journal.pone.0096228

    Article  PubMed  PubMed Central  Google Scholar 

  • Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128

    Article  CAS  PubMed  Google Scholar 

  • Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A (2008) Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 20:628–635. doi:10.1093/annonc/mdn675, 2009

    Article  PubMed  Google Scholar 

  • Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol vol 32(27):2959–2966

    Article  Google Scholar 

  • Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K (1982) A prognostic index in primary breast cancer. Br J Cancer 45(3):361–366

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garner J, Goodfellow P (2004) The Nottingham Prognostic Index Questions for the MRCS vivas, Firstth edn., p 231

    Google Scholar 

Download references

Acknowledgments

Authors are thankful to the Indian Council of Medical Research, Government of India, for financial support. We also extend our thanks to Prof. N. Rajalaxmi, Director academics, Medical Council of India and Dr. Reena Sinha, Associate Proffessor, NMCH. We are also thankful to the Department of Oncology and Pathology, Mahavir Cancer Institute and Research Centre, Patna, S.S. Hospital and Research Institute, Patna and NMCH Patna for providing samples.

Author information

Authors and Affiliations

  1. Research Institute, S. S. Hospital and Research Institute, Patna, Bihar, India

    Aseem Kumar Anshu, Akhileshwari Nath &  Prinyanka

  2. Department of Oncology, S. S. Hospital and Research Institute, Patna, Bihar, India

    J. K. Singh

  3. Department of Obstetrics and Gynaecology, Charak Palika Hospital, New Delhi, India

    Neha Sinha

  4. Department of Medicine, AIIMS, Patna, India

    Shreya Sinha

  5. Department of Zoology, Patna University, Patna, India

    Priyanka Sinha

Authors
  1. Aseem Kumar Anshu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akhileshwari Nath
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prinyanka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Neha Sinha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Priyanka Sinha
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shreya Sinha
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. K. Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prinyanka.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Research Involving Human Participants

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all patients for being included in the study.

Informed Consent

Informed consent was obtained from all patients included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anshu, A.K., Nath, A., Prinyanka et al. Abnormal gene expression leads to poor prognosis in breast cancer patients in Bihar. Comp Clin Pathol 25, 763–768 (2016). https://doi.org/10.1007/s00580-016-2261-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00580-016-2261-x

Keywords

Search

Navigation